Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fatostatin hydrobromide (Fatostatin A HBr) 是一种 SREBP 活化的特异性抑制剂,可抑制 SREBP-1 和 SREBP-2 的活化。它与 SCAP (SREBP 裂解激活蛋白) 结合,抑制 SREBPs 的 ER-Golgi 易位。它具有抗肿瘤作用,能抑制 ob/ob 小鼠的高血糖。它抑制了细胞中成脂基因的转录。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 196 | 现货 | ||
5 mg | ¥ 453 | 现货 | ||
10 mg | ¥ 659 | 现货 | ||
25 mg | ¥ 1,190 | 现货 | ||
50 mg | ¥ 1,980 | 现货 | ||
100 mg | ¥ 3,120 | 现货 | ||
200 mg | ¥ 4,680 | 现货 | ||
500 mg | ¥ 6,970 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 490 | 现货 |
产品描述 | Fatostatin hydrobromide (Fatostatin A HBr) ia an inhibitor of sterol regulatory element binding protein (SREBP). It impairs the activation of SREBP-1 and SREBP-2. |
体外活性 | Fatostatin inhibits the insulin-induced adipogenesis of 3T3-L1 cells and the serum-independent growth of human androgen-independent prostate cancer (DU145) cells. Fatostatin suppresses cell proliferation and anchorage-independent colony formation in both androgen-responsive LNCaP and androgen-insensitive C4-2B prostate cancer cells. Fatostatin blocks the activation of SREBPs in cells in tissue culture.Fatostatin also reduced in vitro invasion and migration in both cell lines. Further, fatostatin causes G2/M cell cycle arrest and induces apoptosis by increasing caspase-3/7 activity and the cleavages of caspase-3 and PARP. |
体内活性 | Fatostatin significantly inhibits subcutaneous C4-2B tumor growth and markedly decreases serum PSA level compared to the control group. Fatostatin blocks increases in body weight, blood glucose, and hepatic fat accumulation in obese ob/ob mice, even under uncontrolled food intake. |
细胞实验 | Cell lines: CHO-K1 cells. Concentrations: 20 μM. Incubation Time: 20 h. Method: On day 0,CHO-K1 cells are plated out onto a 96-well plate in medium A.On day 2,the cells are transiently cotransfected with pCMV-PLAP-BP2(513–1141),pCMV-SCAP,and pAc-β-gal,using Lipofectamine reagent.After incubation for 5 hr,the cells are washed with PBS and then incubated in medium B,in the absence or presence of fatostatin (20 μM) or sterols (10 μg/mL cholesterol and 1 μg/mL 25-hydroxycholesterol).After 20 hr of incubation,an aliquot of the medium is assayed for secreted alkaline phosphatase activity.The cells in each well are lysed and used for measurement of β-galactosidase activities.The alkaline phosphatase activity is normalized by the activity of β-galactosidase. |
动物实验 | Animal Models: Obese (ob/ob) mice (C57BL/6J background). Formulation: 10% DMSO in PBS. Dosages: 30 mg/kg. Administration: intraperitoneal injection |
别名 | Fatostatin HBr, Fatostatin A, Fatostatin A HBr, Fatostatin |
分子量 | 375.33 |
分子式 | C18H18N2S·HBr |
CAS No. | 298197-04-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7 mg/mL (18.65 mM)
Ethanol: 58 mg/mL (154.53 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 2.6643 mL | 13.3216 mL | 26.6432 mL | 66.6081 mL |
5 mM | 0.5329 mL | 2.6643 mL | 5.3286 mL | 13.3216 mL | |
10 mM | 0.2664 mL | 1.3322 mL | 2.6643 mL | 6.6608 mL | |
Ethanol | 20 mM | 0.1332 mL | 0.6661 mL | 1.3322 mL | 3.3304 mL |
50 mM | 0.0533 mL | 0.2664 mL | 0.5329 mL | 1.3322 mL | |
100 mM | 0.0266 mL | 0.1332 mL | 0.2664 mL | 0.6661 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Fatostatin hydrobromide 298197-04-3 Membrane transporter/Ion channel Metabolism NPC1L1 Fatty Acid Synthase Golgi ob/ob inhibit prostate Fatostatin HBr SREBP-mediated cancer mice Fatostatin A Fatostatin A HBr insulin-induced adipogenesis Fatostatin Hydrobromide Fatty Acid Synthase (FASN) gene human expression Inhibitor 125B11 Fatostatin inhibitor